Clinical Trial Update: Dexmedetomidine in the Treatment of Agitation Associated With Dementia (TRANQUILITY II) [Phase 3]

View source ↗

Summary

A Phase 3 trial (TRANQUILITY II) evaluating dexmedetomidine for agitation in dementia has completed with results posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Agitation
• Dementia

Drugs mentioned

• Dexmedetomidine (Dexmedetomidine)

Snippet

Sponsor: BioXcel Therapeutics Inc | Conditions: Agitation, Dementia | Phase 3 | Status: COMPLETED | Results posted: 2025-12-31